retatrutide clinical trial results weight loss 2024 2025 press release Eli Lilly's shows promising in phase 3 Retatrutide produces up to 30.3%

Do not assume it matches your previous vial

Reviewing your current coverage and potentially discussing expanded coverage during enrollment periods could improve your access when Retatrutide launches

Reluctance or inability to share these details is a significant warning sign

J Thorac Oncol 2019;14:1378-89

Supervision required : Texas (mandatory physician oversight with prescriptive authority agreements one MD can delegate to max 7 NPs), Pennsylvania (no independent NP practice yet), Florida (limited autonomy for primary care NPs, but psychiatric NPs generally need physician partnership)

Congenital hypothyroidism due to ectopic sublingual thyroid gland in Prader-Willi Syndrome: a case report